| Topic |
Author |
Posted On |
| Development of FGFR-based Bispecific ADCs |
cataliesw |
2 days, 13 hours ago |
| An appealing and innovative treatment is the bispecific antibody-drug combination (ADC), which delivers targeted cytotoxic drugs with increased efficacy and less non-specific cytotoxic effects while directly targeting tumor-associated cell-surface antigens. Learn more: Development of FGFR-based Bispecific ADCs |
| antibody-drug conjugates |
cataliesw |
6 days, 14 hours ago |
| Antibody-drug conjugates (ADCs) inherit such superiorities and more remarkably, expand the therapeutic window of the conjugated drugs (payloads), which are usually highly toxic and diverse in their biochemical nature. |
| plasmids |
cataliesw |
on 9/12/24 |
| As the leading custom service provider, Creative Biolabs has been keeping a close eye on the development of the epidemic situation and accelerating the development of plasmids. Please feel free to contact us to learn more products and custom production. |
